In a phase I dose-ranging study, Wagner and colleagues evaluated MK-8242 in 47 patients with TP53–wild-type advanced solid tumors, 27 of whom had liposarcoma. The recommended phase II dose was determined to be 400 mg. The ORR was 6.4%, with an ORR of 11.1% in patients with liposarcoma. Three patients achieved partial responses and 31 showed stable disease. The median progression-free survival was 3.4 months overall and 7.8 months in patients with liposarcoma. Taken together, the results of this phase I trial indicate that MK-8242 has an acceptable safety profile at the determined recommended dose, and may have antitumor activity in patients with p53–wild-type tumors, particularly those with liposarcoma. Taken together, the results of this phase I trial indicate that MK-8242 has an acceptable safety profile at the determined recommended dose, and may have antitumor activity in patients with p53–wild-type tumors, particularly those with liposarcoma.